Trapidil
Chemical compound
- C01DX11 (WHO)
- US: Not approved
- In general: ℞ (Prescription only)
- N,N-Diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
- 15421-84-8
N
- 5531
- 5330
N
- EYG5Y6355E
- DTXSID0045416
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- CCN(CC)c1cc(nc2n1ncn2)C
InChI
- InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
N
- Key:GSNOZLZNQMLSKJ-UHFFFAOYSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Trapidil is a vasodilator and an antiplatelet drug.[1][2] It also acts as an antagonist of platelet-derived growth factor.[3]
An analog was assigned the codename AR 12-456.[4]
References
- ^ Büyükafşar K, Yazar A, Düşmez D, Oztürk H, Polat G, Levent A (October 2001). "Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats". Pharmacological Research. 44 (4): 321–328. doi:10.1006/phrs.2001.0864. PMID 11592868.
- ^ Liu M, Sun Q, Wang Q, Wang X, Lin P, Yang M, Yan Y (March–April 2014). "Effect of trapidil in myocardial ischemia-reperfusion injury in rabbit". Indian Journal of Pharmacology. 46 (2): 207–210. doi:10.4103/0253-7613.129320. PMC 3987192. PMID 24741195.
- ^ Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, et al. (December 1994). "Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica". Circulation. 90 (6): 2710–2715. doi:10.1161/01.cir.90.6.2710. PMID 7994812.
- ^ Hering S, Bodewei R, Schubert B, Krause EG, Wollenberger A (1985). "Trapidil and other 5-triazolo-(1, 5-alpha)-pyrimidine derivatives as calcium channel blockers in 108CC5 cells". Biomedica Biochimica Acta. 44 (5): K37–K41. PMID 2415119.
- v
- t
- e
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
Glycoprotein IIb/IIIa inhibitors |
|
---|---|
ADP receptor/P2Y12 inhibitors | |
Prostaglandin analogue (PGI2) | |
COX inhibitors | |
Thromboxane inhibitors | |
Phosphodiesterase inhibitors | |
Other |
Vitamin K antagonists (inhibit II, VII, IX, X) | |||||
---|---|---|---|---|---|
Factor Xa inhibitors (with some II inhibition) |
| ||||
Direct thrombin (IIa) inhibitors |
| ||||
Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e